High cholesterol is one of the most common health concerns worldwide, affecting millions of adults and significantly increasing the risk of atherosclerosis, which ultimately can lead to heart attack and stroke. Hyperlipidaemia and its broader counterpart, dyslipidaemia, are frequent diagnoses in primary care, and in many cases, they come with other chronic conditions like diabetes, hypertension, or kidney disease. This often means patients are prescribed multiple medications at once or in the future, which increases the likelihood of polypharmacy.

While combining treatments can be essential for improving health outcomes, it also raises the risk for drug interactions, side effects, and poor adherence; it might even cause a patient to stop their treatment. In this article, we’ll break down what hyperlipidaemia is, how polypharmacy fits into the picture, and the key strategies for prescribing safely, from selecting the right dose and duration to minimising interactions and ensuring proper monitoring.

Introduction

Most people have heard their doctor talk about “good cholesterol” and “bad cholesterol”, but for many, the difference between the two isn’t entirely clear. If your doctor has ever told you that your LDL (“bad” cholesterol) is high or your HDL (“good” cholesterol) is low, you’re not alone. These changes in lipid levels are more than just lab results; they’re important clues about your cardiovascular health.¹

Hyperlipidaemia is one of the most common cardiovascular risk factors, often found alongside other conditions like diabetes, hypertension, or kidney disease. Because of these comorbidities, many patients require multiple medications, a condition known as polypharmacy. While necessary, polypharmacy can increase the risk of drug interactions, side effects, and poor adherence. That’s why safe prescribing strategies and careful monitoring are essential.

In this article, we’ll break down what hyperlipidaemia and dyslipidaemia really mean, how they differ, and why understanding these conditions is the first step to reducing risks when multiple medications are involved.

Understanding Hyperlipidaemia and Dyslipidaemia

Here we focus on hyperlipidaemia, but there is another term, Dyslipidaemia, which might cause confusion. Let's shed light on what each means.

What is hyperlipidaemia?

Hyperlipidaemia refers to having higher-than-normal levels of certain lipids in your blood, such as low-density lipoprotein (LDL), total cholesterol, triglycerides, or lipoprotein(a), often defined as values above the 90th percentile for the general population. It can also mean having high very-low-density lipoprotein (VLDL) or low high-density lipoprotein (HDL) levels (below the 10th percentile).¹

This condition can result from genetic factors, acquired lifestyle factors, or a combination of both. Left unmanaged, hyperlipidaemia increases the risk of atherosclerosis, heart attack, stroke, and other cardiovascular and cerebrovascular complications.

What is dyslipidaemia?

Dyslipidaemia is a broader term that includes any abnormality in blood lipid levels, whether it’s elevated LDL or triglycerides, reduced HDL, or a combination of changes. Unlike hyperlipidaemia, which focuses on elevated lipid levels, dyslipidaemia also covers patterns where lipids are abnormally low or imbalanced.²

Dyslipidaemia can be primary (caused by genetic conditions) or secondary (developing due to other diseases like diabetes, hypothyroidism, or chronic kidney disease). Regardless of the cause, dyslipidaemia significantly raises the risk of cardiovascular and cerebrovascular events, making early detection and proper management vital.

What is Polypharmacy?

Initially, the term 'polypharmacy' was used to describe the use of multiple drugs and excessive medication intake. Over time, its definition has evolved, and currently, taking five or more medications is considered polypharmacy. This threshold of five drugs is linked to increased risks of negative outcomes like falls, frailty, disability, and mortality in elderly individuals. It is estimated that people over 65 make up one-third of the polypharmacy population.³

Polypharmacy is generally viewed as undesirable and to be avoided, and studies show that inappropriate prescribing often contributes to it. Ageing increases the likelihood of multiple chronic conditions, leading to the need for several medications. As the number of medications rises, so does the chance of drug interactions and adverse drug reactions, harm caused by a medication, even when taken at the recommended doses.⁴

Key Factors in Prescribing for Hyperlipidaemia in Polypharmacy Patients

So let's say your physician has successfully diagnosed hyperlipidaemia and you're warranted for pharmacotherapy besides lifestyle modification; now what should they consider when prescribing for hyperlipidaemia?

Appropriate Drug Selection

There are several drugs that can be prescribed for hyperlipidemia; these include:

• Statins
• Fibrates
• Ezetimibe
• PCSK9 inhibitors

Appropriate Dose

It’s important to start with the lowest effective dose and titrate as needed. A Swiss study of 715 older adults (average age ~80) showed that 47% were taking statins. Among them, statin use was appropriate in about 66%, underused in 18%, and overused in 15%. For those using statins to prevent another heart event, women were more likely to be underusing them, while people who were homebound or taking ten or more medications tended to overuse statins. In those using statins to prevent a first heart event, about 28% were either underusing or overusing statins, but no clear risk factors were found.⁵

Adherence to Therapy

Even though there are effective treatments for lowering LDL cholesterol, many patients who should be treated aren’t getting the right therapy and still have high LDL levels. This gap harms their health, especially those with heart disease. Poor adherence to treatment is a big hurdle, caused by costs, side effects, other health issues, and sometimes doctors not prescribing enough. Sticking to statin therapy is linked to better survival, so improving how well patients follow treatment is key.

Adequate Duration of Therapy

Long-term therapy is usually necessary to manage chronic lipid levels, especially in patients with a high risk of cardiovascular conditions. However, the longer someone stays on lipid-lowering treatment, the greater the chance of drug interactions, as new medications may be added over time for other health issues.

Monitoring for Efficacy and Safety

The most important lab test to get is a fasting lipid profile, which measures LDL, HDL, triglycerides, and total cholesterol. For a fuller picture, tests like VLDL, total cholesterol-to-HDL ratio, and LDL-to-HDL ratio can be added. Patients should fast for 9 to 12 hours, drinking only water, to avoid affecting results, especially triglycerides.⁶

Before starting statins for high LDL, liver function tests are needed to check for liver problems since statins might worsen them. To assess overall risk, doctors should also check Hgb A1c for diabetes, monitor blood pressure for hypertension, test TSH for thyroid issues, and do a urinalysis to detect albuminuria. These tests help weigh the risks and benefits of starting treatment for high cholesterol.⁶

Drug Interactions in Polypharmacy

As mentioned before, when someone is considered to be on polypharmacy, the risk of drug interactions increases. These interactions can be minor or serious, potentially harming the patient and making it harder for them to stick to their treatment.

Common Interaction Risks with Lipid-Lowering Drugs

Lipid-lowering medications, especially statins, are commonly prescribed to manage cholesterol and prevent heart disease. While effective, these drugs can interact with other medications or substances, increasing the risk of side effects like muscle pain or, in rare cases, a serious condition called rhabdomyolysis, which damages muscles.

• Statins and CYP3A4 Inhibitors/Inducers: Some statins, like simvastatin, lovastatin, and atorvastatin, are processed in the body by an enzyme called CYP3A4. Certain medications and even grapefruit juice can block this enzyme, causing statin levels to build up in the blood, which increases the risk of muscle-related side effects.
  Examples include antibiotics like clarithromycin, antifungals like itraconazole, and some HIV medications. Other drugs, like verapamil or diltiazem (used for blood pressure), have a milder effect but still require careful use with statins. Pravastatin, rosuvastatin, and pitavastatin are less affected by these interactions because they are cleared from the body differently.⁷ 
• Fibrates and Statins: Fibrates, another type of cholesterol-lowering drug, can increase the risk of muscle problems when taken with statins. For example, gemfibrozil can interfere with how statins are processed, raising their levels in the blood and increasing the chance of muscle damage.⁸
• Warfarin and Fibrates: Fibrates can also interact with warfarin, a blood thinner, affecting how well it controls blood clotting. This can lead to a higher risk of bleeding or clotting if not monitored closely.⁹

Recognising High-Risk Combinations

Certain drug combinations can be particularly risky for people taking multiple medications. Here are some examples of dangerous overlaps to watch for:

• Statins and Quinolone Antibiotics: Combining statins with quinolone antibiotics (like ciprofloxacin) can increase the risk of muscle or liver problems, especially in older adults or those with kidney issues. These combinations may lead to side effects that require close monitoring of liver and muscle function. If problems arise, stopping the drugs promptly, staying hydrated, and, in severe cases, medical interventions like dialysis can help reverse the effects.¹⁰
• Statins with Cyclosporine or Gemfibrozil: Cyclosporine (used in transplant patients) and gemfibrozil can significantly increase statin levels in the blood, raising the risk of muscle damage. These combinations should be avoided or used under strict medical supervision.¹¹

Understanding these risks and working closely with healthcare providers can help ensure safe and effective use of cholesterol-lowering medications while minimising harmful interactions.

Minimising Drug Interaction Risks in Hyperlipidaemia with Polypharmacy

Managing cholesterol with medications like statins is critical for many people, especially those with heart disease risk. However, when patients take multiple medications (polypharmacy), the risk of drug interactions increases. Here are practical strategies to reduce these risks while ensuring effective treatment for hyperlipidaemia.

Comprehensive Medication Review

A thorough review of all medications is a key step in preventing harmful drug interactions. This includes:

• Prescription Medications: Doctors should review all prescribed drugs to identify potential conflicts with cholesterol-lowering medications like statins. For example, some drugs can increase statin levels in the blood, raising the risk of side effects like muscle pain.
• Over-the-Counter (OTC) Drugs: Common OTC medications, such as pain relievers or antacids, can sometimes interact with cholesterol drugs. Patients should share all OTC drugs they take with their healthcare provider.
• Herbal Supplements: Many people use supplements like St. John’s wort or fish oil, which can affect how cholesterol medications work. A complete list of supplements helps doctors spot potential issues.

Regular medication reviews, especially for patients with conditions like heart disease, high blood pressure, or diabetes, can catch risky combinations early. This is particularly important since studies show that up to 60% of older adults take five or more medications, increasing the chance of interactions.

Dose Adjustment Strategies

Adjusting medication doses can help minimise risks, especially for vulnerable groups:

• Lower Starting Doses for Older Adults or Those with Liver/Kidney Issues: Older patients or those with reduced liver or kidney function are more sensitive to medications. Starting with lower doses of statins can reduce the risk of side effects like muscle damage. For example, patients with kidney issues may need smaller doses to prevent drug buildup in the body.¹²
• Tailored Dosing Based on Experience: Some patients stop taking statins due to side effects like muscle pain from past treatments. Doctors can try lower-intensity statins or different cholesterol-lowering drugs to find a safer option that works.¹²

These adjustments can make treatment safer and encourage patients to stick with their medications, especially since fear of side effects is a common reason people avoid or stop taking statins.

Staggered Dosing and Timing Adjustments

The timing of when medications are taken can help prevent interactions:

• Preventing Absorption-Related Interactions: Some drugs, when taken together, can affect how well the body absorbs cholesterol-lowering medications. For example, taking statins at a different time of day from certain other drugs or supplements (like fibrates or grapefruit juice) can reduce the risk of interactions. Doctors may suggest taking statins in the evening, as they work best at night, while other medications might be taken in the morning.
• Simplifying Schedules: For patients juggling multiple medications, combining drugs into once-daily doses or using fixed-dose combinations (where multiple drugs are in one pill) can make schedules easier to follow and reduce the chance of mistakes that lead to interactions.

Use of Drug Interaction Checkers and Clinical Decision Support Tools

Technology can play a big role in keeping patients safe:

• Drug Interaction Checkers: Online tools and apps allow doctors and pharmacists to quickly check for potential interactions between statins and other medications. These tools flag risky combinations, like statins with certain antibiotics or antifungals, helping healthcare providers make safer prescribing decisions.¹³
• Clinical Decision Support Tools: Electronic health record (EHR) systems often include alerts that warn doctors about potential drug interactions when prescribing. These tools use patient data, like medical history and current medications, to suggest safer treatment plans. For example, they might recommend a statin less likely to interact with other drugs a patient is taking.¹³
• Patient Education: Many patients avoid statins due to fears of side effects, often fuelled by misinformation online or past experiences with other medications. Doctors can use decision support tools to explain why statins are safe for most people and address concerns, such as the fact that studies show little difference in side effects between statins and placebos.¹³

By using these assessment tools alongside open, honest conversations, healthcare providers can help patients feel more confident and engaged in their treatment plans. This approach is especially valuable for those who prefer lifestyle changes over medications. While diet and exercise can improve cardiovascular health and reduce the need for multiple drugs, thereby lowering the risks of polypharmacy and drug interactions, they often aren’t enough on their own to bring cholesterol down to safe levels and reduce heart disease risk. 

Regular follow-ups are important to track progress, ensure cholesterol goals are met, and adjust the plan to include medications like statins when necessary, balancing benefits and minimising side effects, especially in older adults.

Practical Tips for Clinicians

Managing cholesterol medications in patients with polypharmacy requires careful planning to avoid drug interactions and improve outcomes. Here are key strategies for clinicians to ensure safe and effective treatment.

• Collaborating with Pharmacists for Medication Reconciliation: Partner with pharmacists to review patients’ full medication lists, including prescriptions, over-the-counter drugs, and supplements.
  Pharmacists can spot potential interactions, such as those between statins and other drugs, and suggest safer alternatives or dose adjustments. They also ensure medication records are accurate, reducing risks from discrepancies or duplications. Regular collaboration helps tailor regimens to each patient’s needs, enhancing safety and adherence.¹³
• Educating Patients on Warning Signs of Interactions: Teach patients to recognise symptoms of drug interactions, like muscle pain, weakness, or unusual fatigue, which could signal issues with cholesterol medications.
  Explain how to take medications correctly and why avoiding certain foods (like grapefruit juice) matters. Clear, simple guidance empowers patients to report problems early, allowing quick adjustments to prevent serious side effects.¹³
• Encouraging Lifestyle Modification to Reduce Medication Burden: Promote diet and exercise as complements to cholesterol medications, as many patients prefer these over adding drugs. While lifestyle changes alone often don’t lower cholesterol enough, they can reduce the need for multiple medications, simplifying regimens and lowering interaction risks. Regular follow-ups ensure patients meet cholesterol goals, with medication added only if needed.¹³ 

These steps, supported by tools like the Beers Criteria and medication review systems, help clinicians balance patient preferences, safety, and effective cholesterol management in polypharmacy settings.

Conclusion

Managing hyperlipidaemia in patients with polypharmacy requires careful prescribing to balance the benefits of cholesterol-lowering medications with the risks of drug interactions and side effects. By selecting appropriate drugs, adjusting doses, and monitoring patients closely, clinicians can reduce cardiovascular risks while minimising harm. 

Collaboration with pharmacists, patient education, and the use of tools like drug interaction checkers are essential for safe and effective treatment. Encouraging lifestyle changes alongside medications can further simplify regimens and lower the medication burden. This thoughtful approach ensures patients achieve better heart health without compromising safety, especially for older adults or those with multiple chronic conditions.

FAQs

Can polypharmacy be avoided in hyperlipidaemia?

Polypharmacy can’t always be avoided in hyperlipidaemia, especially for patients with multiple health conditions like diabetes or heart disease. However, clinicians can reduce the medication burden by promoting lifestyle changes, such as a heart-healthy diet and exercise, which may lower the need for multiple drugs. Regular medication reviews can also help minimise polypharmacy while effectively managing cholesterol.

What is the safest statin for patients on multiple medications?

Statins like pravastatin, rosuvastatin, and pitavastatin are often safer for patients on multiple medications because they are less likely to interact with drugs processed by the CYP3A4 enzyme. However, the safest choice depends on the patient’s other medications, health conditions, and kidney or liver function.

How often should lipid levels be monitored in polypharmacy patients?

Lipid levels should typically be checked every three to six months in polypharmacy patients, especially when starting or adjusting cholesterol medications. A fasting lipid profile (measuring LDL, HDL, triglycerides, and total cholesterol) helps assess treatment effectiveness and detect potential issues. More frequent monitoring may be needed for patients with high-risk conditions, recent medication changes, or signs of side effects like muscle pain.

Summary

This article explores safe prescribing strategies for managing hyperlipidaemia in polypharmacy patients, emphasising the balance between reducing cardiovascular risk and minimising drug interactions. It covers the differences between hyperlipidaemia and dyslipidaemia, the risks of adverse drug reactions with medications like statins and fibrates, and practical approaches such as medication reviews, dose adjustments, staggered dosing, and clinical decision support tools. By collaborating with pharmacists, educating patients on interaction warning signs, and encouraging lifestyle modifications, clinicians can enhance medication safety and improve patient adherence to achieve better heart health.